cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
Published 11 months ago • 64 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:27
managing cardiotoxicity associated with the use of ibrutinib
-
2:06
identification of genetic markers associated with ibrutinib-related cardiovascular toxicity
-
4:42
ibrutinib, bruton’s tyrosine kinase inhibitor, for non-hodgkin lymphoma
-
0:38
pain management for patients with scd and thalassemia in lebanon
-
4:48
an insight into the management of cytopenias in mf
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
21:38
drawing the line: the rationale behind blood tube collection order
-
9:44
cystic pancreatic masses
-
4:22
discover versiti diagnostic labs, clinical trials and biomaterials | versiti
-
1:06
derive trial update: did vs dvd in newly diagnosed mm
-
0:42
the limited access to novel therapeutics for sickle cell disease in lmics
-
1:23
vladimir sheynzon, md - interventional radiologist
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
0:57
the importance of integrating basic science sessions into ascat 2024
-
1:34
car-t expansion is associated with treatment response, crs, and cytopenia in patients with r/r mm
-
2:45
swift-seq: single-cell rna sequencing of ctcs for patients with multiple myeloma and precursors
-
1:07
characterizing distinct mechanisms of heart failure in patients with sickle cell disease
-
2:02
tki and checkpoint inhibitor combinations for kidney cancer: the immotion151 trial
-
2:42
rcmi 2021 | 18.01.01 - tsang-wei tu